Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR7 | P34969 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16990259 | 0.84 | HTR6 (0.50) | HTR6TDO2HTR2AHTR7L3MBTL1 | |
| SCHEMBL16990424 | 0.84 | HTR6 (0.51) | HTR6TDO2HTR2AHTR7L3MBTL1 | |
| SCHEMBL16698358 | 0.84 | HTR6 (0.46) | HTR6HTR2AHTR7L3MBTL1DRD2 | |
| SCHEMBL18045682 | 0.83 | HTR6 (0.47) | HTR6HTR2AHTR7L3MBTL1DRD2 | |
| SCHEMBL16698341 | 0.81 | HTR6 (0.45) | HTR6HTR2AHTR7L3MBTL1DRD2 | |
| SCHEMBL16703414 | 0.81 | HTR6 (0.49) | HTR6HTR2AHTR7L3MBTL1DRD2 | |
| SCHEMBL16990428 | 0.81 | HTR6 (0.55) | HTR6TDO2HTR2AHTR7L3MBTL1 | |
| SCHEMBL16703434 | 0.80 | HTR6 (0.48) | HTR6HTR2AHTR7L3MBTL1DRD2 | |
| SCHEMBL16990292 | 0.79 | HTR6 (0.50) | HTR6TDO2HTR2AHTR7L3MBTL1 | |
| SCHEMBL16990273 | 0.78 | HTR6 (0.51) | HTR6HTR2AHTR7L3MBTL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758505-B2 | 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | ITEOS THERAPEUTICS (BE) | 2017-09-12 | — | — | US | disclosed |
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225367-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 61/4885TDO2 1/4885HTR2A 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.